ALLMedicine™ Ankylosing Spondylitis Center

Apr 15th, 2021 - This study aimed to determine the relation between temporomandibular disorder (TMD) and ankylosing spondylitis (AS) bidirectionally and ascertain the important comorbidities for AS occurrence in TMD patients. We conducted this population-based coh...

Apr 13th, 2021 - Ankylosing spondylitis is a complex and progressive autoimmune inflammatory disease with a worldwide prevalence ranging up to 0.9%. Several systematic reviews and meta-analyses of traditional Chinese medicine alternative therapies, such as acupunc...

Apr 9th, 2021 - The objective of this study is to establish an ankylosing spondylitis (AS) thoracolumbar fracture finite element (FE) model and provide a proper posterior fixation choice from the biomechanical perspective. The ankylosing spondylitis T9-L5 FE mode...

Apr 8th, 2021 - Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies. To assess the malignancy risk in secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients. T...

Apr 8th, 2021 - The present study aimed to investigate the effects of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT)-1 on ankylosing spondylitis and its underlying mechanisms. Proteoglycan induced ankylosing spondylitis (PGIA) mouse model...

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

Apr 15th, 2021 - This study aimed to determine the relation between temporomandibular disorder (TMD) and ankylosing spondylitis (AS) bidirectionally and ascertain the important comorbidities for AS occurrence in TMD patients. We conducted this population-based coh...

Apr 13th, 2021 - Ankylosing spondylitis is a complex and progressive autoimmune inflammatory disease with a worldwide prevalence ranging up to 0.9%. Several systematic reviews and meta-analyses of traditional Chinese medicine alternative therapies, such as acupunc...

Apr 9th, 2021 - The objective of this study is to establish an ankylosing spondylitis (AS) thoracolumbar fracture finite element (FE) model and provide a proper posterior fixation choice from the biomechanical perspective. The ankylosing spondylitis T9-L5 FE mode...

Apr 8th, 2021 - Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies. To assess the malignancy risk in secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients. T...

Apr 8th, 2021 - The present study aimed to investigate the effects of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT)-1 on ankylosing spondylitis and its underlying mechanisms. Proteoglycan induced ankylosing spondylitis (PGIA) mouse model...

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...